Drugs for Hereditary Breast Ovarian Cancer Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 51)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
2 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
3 |
|
Zoledronic acid |
Approved |
Phase 2 |
|
118072-93-8 |
68740 |
Synonyms:
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonate
(1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonate
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
2-(Imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
ácido zoledrónico
ACLASTA
Aclasta®|CGP-42446|CGP-42446A|Reclast®|zoledronate|Zometa®
ANHYDROUS ZOLEDRONIC ACID
CGP-42446
CGP-42446A
Novartis brand OF zoledronic acid
|
Reclast
ZERLINDA
ZOL
ZOL446
ZOLEDRONATE
Zoledronic acid
Zoledronic acid anhydrous
ZOLEDRONIC ACID HYDRATE
ZOLEDRONIC ACID MONOHYDRATE
ZOLEDRONIC ACID, ANHYDROUS
Zometa
Zometa Concentrate
|
|
4 |
|
Carboplatin |
Approved |
Phase 1, Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
5 |
|
Durvalumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
6 |
|
Olaparib |
Approved |
Phase 1, Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
7 |
|
Imidazole |
Experimental, Investigational |
Phase 2 |
|
288-32-4 |
795 |
Synonyms:
{Pyrro[b]monazole}
1,3-Diaza-2,4-cyclopentadiene
1,3-Diazole
1H-Imidazole
Al-imidazole
Cu-imidazole
Glyoxalin
Glyoxaline
Him
IMD
Imidazol
Imidazole
Imidazole acetate
|
Imidazole citrate
Imidazole conjugate monoacid
Imidazole monohydrochloride
Imidazole monophosphonate
Imidazole sodium
Imidazolium chloride
Iminazole
Imutex
Miazole
N,N'-1,2-ethenediylmethanimidamide
N,N'-vinyleneformamidine
Pyrro(b)monazole
Pyrro[b]monazole
|
|
8 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
9 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
10 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
11 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
12 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
13 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
14 |
|
Liposomal doxorubicin |
|
Phase 2 |
|
|
|
15 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
16 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
17 |
|
Antineoplastic Agents, Immunological |
|
Phase 1, Phase 2 |
|
|
|
18 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 1 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
19 |
|
Sargramostim |
Approved, Investigational |
Phase 1 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
20 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 1 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
21 |
|
Pancrelipase |
Approved, Investigational |
Phase 1 |
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
22 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 1 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
23 |
|
Molgramostim |
Investigational |
Phase 1 |
|
99283-10-0 |
|
Synonyms:
|
MOLGRAMOSTIM (GENETICAL RECOMBINATION)
SCH-39300
|
|
24 |
|
Veliparib |
Investigational |
Phase 1 |
|
912444-00-9 |
11960529 |
Synonyms:
(2R)-2-(7-CARBAMOYL-1H-BENZIMIDAZOL-2-YL)-2-METHYLPYRROLIDINIUM
2-((2R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
2-((R)-2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
2-(2-Methylpyrrolidin-2-yl)-1H-1,3-benzodiazole-7-carboximidate
2-(2-Methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide
2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide
|
2-[(R)-2-METHYLPYRROLIDIN-2-YL]-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
ABT 888
ABT-888
PARP-1 INHIBITOR ABT-888
VELIPARIB
|
|
25 |
|
Vitamins |
|
Phase 1 |
|
|
|
26 |
|
Folate |
|
Phase 1 |
|
|
|
27 |
|
Vaccines |
|
Phase 1 |
|
|
|
28 |
|
Vitamin B9 |
|
Phase 1 |
|
|
|
29 |
|
Vitamin B Complex |
|
Phase 1 |
|
|
|
30 |
|
Hematinics |
|
Phase 1 |
|
|
|
31 |
|
Albumin-Bound Paclitaxel |
|
Phase 1 |
|
|
|
32 |
|
Antimitotic Agents |
|
Phase 1 |
|
|
|
33 |
|
Tubulin Modulators |
|
Phase 1 |
|
|
|
34 |
|
Pancreatin |
|
Phase 1 |
|
|
|
35 |
|
Caffeine |
Approved |
|
|
58-08-2 |
2519 |
Synonyms:
1,3,7-TRIMETHYL-2,3,6,7-TETRAHYDRO-1H-PURINE-2,6-DIONE
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-TRIMETHYLPURINE-2,6-QUINONE
1,3,7-Trimethylxanthine
137X
1-Methyltheobromine
1-Methyl-theobromine
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
7-Methyl theophylline
7-Methyltheophylline
Alert-Pep
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anoquan
Berlin-chemie brand OF caffeine
Bristol-myers squibb brand OF caffeine
Cafamil
CAFCIT
Cafecon
Cafeina
Cafeína
Cafeine
Caféine
Cafergot
Caffedrine
Caffedrine Caplets
Caffein
Caffeine
CAFFEINE MELTING POINT STANDARD
Caffeine Pure
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeinum
Caffine
Cafipel
CFF
Coffein
COFFEINE
Coffeinum
Coffeinum N
Coffeinum purrum
Compound 65
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Durvitan
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA NO. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline brand OF caffeine
Guaranine
Hycomine
Invagesic
|
Invagesic Forte
Keep Alert
Kofein
Koffein
Lanorinal
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura brand OF caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Migergot
Miudol
Monohydrate caffeine
Monomethyl Derivative of Theophylline
Natural Caffeinum
Nix Nap
No doz
Nodaca
No-Doz
NODOZ
NODOZ CAPLETS AND CHEWABLE TABLETS
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
NSC-5036
Organex
Orphengesic
Orphengesic Forte
Passauer brand OF caffeine
Pep-Back
Percoffedrinol N
Percutaféine
Peyona®
Phensal
Pierre fabre brand OF caffeine
PRO-PLUS
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick pep
Quick-pep
QuickPep
Refresh'n
Republic drug brand OF caffeine
Respia
Seid brand OF caffeine
SK 65 Compound
Stim
Synalgos-Dc
Teina
Teína
Thein
Theine
Theobromine ME
Theophylline ME
Thompson brand 1 OF caffeine
Thompson brand 2 OF caffeine
Triad
Ultra Pep-Back
Vivarin
Wake-Up
Wigraine
YEAST-VITE
ZANTHINE
|
|
36 |
|
Zinc cation |
Approved, Experimental, Investigational |
|
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
37 |
|
Selenium |
Approved, Investigational, Vet_approved |
|
|
7783-07-5, 7782-49-2 |
533 |
Synonyms:
[SeH2]
Dihydrogen monoselenide
Dihydrogen selenide
H2Se
Hydrogen selenide, 75Se-labeled
Hydroselenate
Hydroselenic acid
Se(2+)
Se2+
Selane
Selanediide
Selen
|
Selenide
Selenide(2-)
Selenio
Sélénium
Selenium dication
Selenium dihydride
Selenium elemental
Selenium hydride
Selenium hydride (seh2)
Selenium ion (se2+)
Selenium metallicum
Selenium, elemental
|
|
38 |
|
Lycopene |
Approved, Investigational |
|
|
502-65-8 |
446925 |
Synonyms:
(6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene
(6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-Octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene
(all-e)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene
(all-E)-Lycopene
all trans Lycopene
all-trans-Lycopene
E160D
E-160D(III)
FEMA NO. 4110
INS NO.160D(III)
|
INS-160D(III)
LYC O mato
LYCOMATO
Lycopene
NSC-407322
Pro lycopene
Pro-lycopene
psi,psi-Carotene
trans-Lycopene
ψ,ψ-Carotene
|
|
39 |
|
Curcumin |
Approved, Investigational |
|
|
458-37-7, 84765-67-3 |
969516 |
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
14a-Methyl-9,19-cyclo-5a,9b-cholestane-3b,6a-diol
C.I. 75300
C.I. natural yellow 3
CI natural yellow 3
CI-75300
Cucurmin
Curcuma
CURCUMIN
Curcumin I
Diferaloylmethane
Diferuloylmethane
e 100
E100
E-100
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
|
Hydrastis
INS NO. 100(I)
INS-100(I)
Kacha haldi
Merita earth
Natural yellow 3
NSC-32982
NSC-687842
Orange root
Safran d'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yellow, turmeric
Yo-kin
|
|
40 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
41 |
|
Indole-3-carbinol |
Investigational |
|
|
700-06-1 |
3712 |
Synonyms:
(1H-Indol-3-yl)methanol
1H-indol-3-Ylmethanol
1H-Indole-3-methanol
3-(Hydroxymethyl)indole
3-Hydroxymethylindole
3-hydroxymethylindole|3-indolemethanol|3-indolylcarbinol|I3C
3-Indolecarbinol
|
3-Indolylcarbinol
3-Indolylmethanol
I3c CPD
Indinol
INDOLE-3-CARBINOL
Indole-3-methanol
NSC-525801
|
|
42 |
|
Indole |
Experimental |
|
|
120-72-9 |
798 |
Synonyms:
1-Azaindene
1-Benzazole
2,3-Benzopyrrole
Benzo[b]pyrrole
|
|
|
43 |
|
Resveratrol |
Investigational |
|
|
501-36-0 |
445154 |
Synonyms:
(E)-2-(3,5-Dihydroxyphenyl)-1-(4-hydroxyphenyl)ethene
(E)-3,4',5-Trihydroxystilbene
(E)-3,4’,5-Trihydroxystilbene
(e)-5-(2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(p-Hydroxystyryl)resorcinol
(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
(e)-Resveratrol
3,4',5-Stilbenetriol
3,4',5-stilbenetriol|3,5,4'-trihydroxystilbene|trans-resveratrol
3,4',5-Trihydroxystilbene
3,4',5-Trihydroxy-trans-stilbene
3,4’,5-Stilbenetriol
3,4’,5-Trihydroxystilbene
3,4’,5-Trihydroxy-trans-stilbene
|
3,5,4'-Trihydroxystilbene
3,5,4'-TRIHYDROXY-TRANS-STILBENE
5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol
5-[(e)-2-(4-Hydroxyphenyl)vinyl]benzene-1,3-diol
BIA 6-512
BIA-6-512
NSC-327430
Resveratrol
SRT 501
SRT-501
trans Resveratrol
trans-3,4',5 - Trihydroxystilbene
trans-3,5,4’-Trihydroxystilbene
trans-3,5,4'-Trihydroxystilbene
trans-Resveratrol
|
|
44 |
|
Genistein |
Investigational |
|
|
446-72-0 |
5280961 |
Synonyms:
4',5, 7-Trihydroxyisoflavone
4,5,7-Trihydroxy iso-flavone
4',5,7-Trihydroxyisoflavone
4',5,7-Trihydroxy-isoflavone
5,7,4'-Trihydroxyisoflavone
5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
FW-635I-2
Genestein
GENISTEIN
|
Genistein 85% HPLC
Genisteol
Genisterin
NPI-031L
NSC-36586
Prunetol
SIPI-807-1
Sophoricol
|
|
45 |
|
Hormones |
|
|
|
|
|
46 |
|
Trace Elements |
|
|
|
|
|
47 |
|
Micronutrients |
|
|
|
|
|
48 |
|
Carotenoids |
|
|
|
|
|
49 |
|
Phytoestrogens |
|
|
|
|
|
50 |
|
Antioxidants |
|
|
|
|
|
Interventional clinical trials:
(show all 50)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study |
Completed |
NCT02562170 |
Phase 4 |
|
2 |
Evaluating the Effectiveness of Inquiry Based Stress Reduction (IBSR) Intervention Versus Regular Care of no Treatment on Well-being, Optimism and Health Behavior of BRCA1/2 Carriers: A Randomized Controlled Trial, RCT. |
Unknown status |
NCT03162276 |
Phase 3 |
|
3 |
Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE Trial). |
Unknown status |
NCT02978495 |
Phase 2 |
Doxorubicin;Carboplatin;Paclitaxel;Cyclophosphamide |
4 |
A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery That Results in Removal of Both Ovaries |
Completed |
NCT00305695 |
Phase 2 |
Zoledronic Acid |
5 |
Pilot Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers |
Completed |
NCT01367639 |
Phase 2 |
|
6 |
Search Allelic Imbalance of Expression of BRCA Genes in Hereditary Risk of Breast and/or Ovarian Cancer |
Completed |
NCT01333748 |
Phase 2 |
|
7 |
A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies. |
Recruiting |
NCT02264678 |
Phase 1, Phase 2 |
Administration of ceralasertib in combination with carboplatin;Administration of ceralasertib;Administration of ceralasertib in combination with olaparib;Administation of ceralasertib in combination with durvalumab |
8 |
Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients |
Completed |
NCT02019524 |
Phase 1 |
|
9 |
A Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies |
Completed |
NCT00535119 |
Phase 1 |
Carboplatin;Paclitaxel;Veliparib |
10 |
Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles for Stomach, Pancreas, Breast and Ovarian Cancer |
Completed |
NCT03304210 |
Phase 1 |
PIPAC with Abraxane |
11 |
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer |
Completed |
NCT00892736 |
Phase 1 |
Veliparib |
12 |
A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers (Familial Breast and Ovarian Cancer) and Sporadic Triple Negative Breast Cancer and Ovarian Cancer |
Completed |
NCT01445418 |
Phase 1 |
AZ2281 + Carboplatin |
13 |
Cohort Study on Characters and Distribution of Inherited Susceptible Genes Among Epithelial Ovarian Cancer Patients and Their Relatives in the North of China |
Unknown status |
NCT03015376 |
|
|
14 |
Evaluation of the Adhesion to the Network of Care of People at Genetic Risk of Cancer in Midi-Pyrénées (GENEPY) |
Unknown status |
NCT03979612 |
|
|
15 |
Tissue Expansion in Breast Reconstruction Without Drains: A Study Using a Tissue Expander That Collects Periprosthetic Fluid |
Completed |
NCT03784859 |
|
|
16 |
Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer: Using Mental Models to Develop Culturally Targeted Media |
Completed |
NCT03075540 |
|
|
17 |
Strategies to Increase the Identification, Genetic Counseling Referral and Genetic Testing for Women at Risk for Hereditary Breast and/or Ovarian Cancer |
Completed |
NCT02786147 |
|
|
18 |
Attitudes About Childbearing And Fertility In Women Seeking Genetic Testing For Inherited Breast And Ovarian Cancer Syndromes (HBOC) |
Completed |
NCT00829959 |
|
|
19 |
Statewide Communication to Reach Diverse Low Income Women |
Completed |
NCT02956681 |
|
|
20 |
University of Southern California (USC) Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing |
Completed |
NCT02324062 |
|
|
21 |
Genetic Risk: Whether, When, and How to Tell Adolescents |
Completed |
NCT03421327 |
|
|
22 |
Telemedicine vs. Face-to-Face Cancer Genetic Counseling in Rural Oncology Clinics |
Completed |
NCT00609505 |
|
|
23 |
Testing an Intelligent Tutoring System Intervention to Enhance Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer |
Completed |
NCT03511690 |
|
|
24 |
Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling |
Completed |
NCT03225170 |
|
|
25 |
A Randomized Controlled Trial to Enhance the Use of Genetic Counseling and Testing in Latinas |
Completed |
NCT04544501 |
|
|
26 |
Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer |
Completed |
NCT02560818 |
|
|
27 |
Testing a Culturally Adapted Telephone Genetic Counseling Intervention to Enhance Genetic Risk Assessment in Underserved Latinas at Risk of Hereditary Breast and Ovarian Cancer |
Completed |
NCT03959267 |
|
|
28 |
Risk-Reducing Surgeries of Salpingo-oophorectomy With/Without Hysterectomy for Carriers With Mutation Genes of Hereditary Ovarian Cancer |
Recruiting |
NCT03294343 |
|
|
29 |
PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations |
Recruiting |
NCT02302742 |
|
|
30 |
Reporting Adult-Onset Genomic Results to Pediatric Biobank Participants and Parents |
Recruiting |
NCT03832985 |
Early Phase 1 |
|
31 |
Familial Investigations of Childhood Cancer Predisposition |
Recruiting |
NCT03050268 |
|
|
32 |
Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection |
Recruiting |
NCT04668521 |
|
|
33 |
Evaluation of the Circulating Concentration of Olfactomédine 4 (OLFM4) in Women With a BRCA1 or 2 Gene Mutation or at High Risk of Developing Breast Cancer, According to the Imaging |
Recruiting |
NCT02653105 |
|
|
34 |
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland |
Recruiting |
NCT03124212 |
|
|
35 |
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome |
Recruiting |
NCT04009148 |
|
|
36 |
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation |
Recruiting |
NCT03667417 |
|
|
37 |
Prospective Randomized Multicenter Trial to Assess the Efficacy of a Structured Physical Exercise Training and Mediterranean Diet in Women With BRCA1/2 Mutations |
Recruiting |
NCT02516540 |
|
|
38 |
Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes. |
Recruiting |
NCT03246841 |
|
|
39 |
Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes |
Recruiting |
NCT04494945 |
|
|
40 |
Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome |
Recruiting |
NCT04508764 |
|
|
41 |
Study of Quality of Life Post Preventive Salpingo-oophorectomy in Healthy BRCA1/2 and PALB2 Mutation Carriers |
Recruiting |
NCT05409222 |
|
|
42 |
Prospective Randomized Multicenter Trial to Assess the Feasibility of a Structured Physical Exercise Training and Mediterranean-style Diet in Women With BRCA1/2 Mutations |
Active, not recruiting |
NCT02087592 |
|
|
43 |
WISP (Women Choosing Surgical Prevention) |
Active, not recruiting |
NCT02760849 |
|
|
44 |
Radical Fimbriectomy for Young BRCA Mutation Carriers at Risk of Pelvic Serous Carcinoma |
Active, not recruiting |
NCT01608074 |
|
|
45 |
Effects of a Nutritional Intervention in DNA Damage of Patients With Hereditary Breast and Ovarian Cancer Syndrome |
Active, not recruiting |
NCT05306002 |
|
|
46 |
Direct Information to At-risk Relatives - a Randomized Controlled Multicentre Trial of Healthcare-assisted Versus Family-mediated Disclosure of Hereditary Cancer Risk Information in High-risk Families in Sweden |
Enrolling by invitation |
NCT04197856 |
|
|
47 |
Informing Latinas About HBOC Risk: a Randomized Controlled Trial |
Enrolling by invitation |
NCT05130606 |
|
|
48 |
Testing Scalable Communication Modalities for Returning Breast Cancer Genetic Research Results to African American Women |
Not yet recruiting |
NCT04407611 |
|
|
49 |
A Comparative Effectiveness Study of Cancer Risk Management for Women at Elevated Genetic Risk of Ovarian Cancer |
Not yet recruiting |
NCT01445275 |
|
|
50 |
Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women (18-40 Years) Exposed to a High Familial Breast/Ovarian Cancer Risk |
Terminated |
NCT02705924 |
|
|
|